Delivery Order SPE2DB20D3505-SPE2DB25FT7T7

Award Date 1/10/25
Potential Completion Date 1/13/25
Potential Value $25K
Ultimate Awardee
Not listed
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Conshohocken, PA 19428, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This is a delivery order awarded by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor, for the supply of OZEMPIC 0.25-0.5 MG/DOSE PEN 3ML. The contract has a ceiling value of $4,888.26 and is a firm fixed price contract. The ultimate completion date is August 1, 2024. Amerisourcebergen holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical valued at up to $999,999,999 through December 2025, which serves as...
This is a delivery order contract awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor, for the supply of OZEMPIC 0.25-0.5 MG/DOSE PEN 3ML. The contract has a fixed price of $23,812.83 and an ultimate completion date of July 25, 2024. This delivery order is part of a larger Indefinite Delivery Contract (IDC) between AmerisourceBergen and the DLA Troop Support Medical, valued at up to $999,999,999 through December 2025, for delivering...
This is a delivery order contract awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $3,325.20, is for the delivery of OZEMPIC 0.25-0.5 MG/DOSE PEN 3ML, a prescription medication. The contract is a Firm Fixed Price, Delivery Order contract with a completion date of January 3, 2025. There is no set-aside designation for this award. AmerisourceBergen holds a larger Indefinite...
This is a delivery order awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp Corporate Office Division for the supply of OZEMPIC 0.25-0.5 MG/DOSE PEN 3ML, a pharmaceutical product. The award, valued at $27,412.22, has a firm-fixed-price contract type and an ultimate completion date of September 27, 2024. This delivery order is part of a larger Indefinite Delivery Contract (IDC) between AmerisourceBergen and the DLA Troop Support Medical, which has a potential value of...
This is a $5,599.68 delivery order awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corporation for the supply of OZEMPIC 0.25-0.5 MG/DOSE PEN 3ML. The contract has a firm fixed price and a period of performance through July 24, 2024. This delivery order is associated with a larger Indefinite Delivery Contract (IDC) between AmerisourceBergen and DLA Troop Support Medical, valued at up to $999,999,999 through December 2025, for providing a comprehensive range of medical...
This is a federal delivery order contract awarded by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distribution company, for the supply of OZEMPIC 0.25-0.5 MG/DOSE PEN 3ML. The contract has a firm fixed price of $11,033.78 and a completion date of June 14, 2024. Amerisourcebergen Drug Corp holds a larger Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued up to $999,999,999.00 through December 31, 2025, which serves as the...
This is a federal contract award from the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $35,563.97 firm fixed-price delivery order is for the supply of OZEMPIC 0.25-0.5 MG/DOSE PEN 3ML, a medication used for the treatment of diabetes. The contract has an ultimate completion date of January 9, 2025. Amerisourcebergen holds a significant $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop...
This is a Firm Fixed Price Delivery Order awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor, for the supply of Ozempic 0.25-0.5 mg/dose pens. The $14,369.56 contract has a period of performance through July 16, 2024. AmerisourceBergen holds a $999,999,999 Indefinite Delivery Contract (IDC) with DLA Troop Support Medical to provide a comprehensive range of pharmaceutical products and medical supplies, including specialty...
This is a firm fixed-price delivery order contract awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $10,824.15, is for the provision of OZEMPIC 0.25-0.5 MG/DOSE PEN 3ML, a diabetes medication. The contract has an ultimate completion date of January 7, 2025 and does not have a set-aside designation, indicating open competition. AmerisourceBergen holds a $999,999,999...
This is a delivery order contract awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor, for the supply of OZEMPIC 0.25-0.5 MG/DOSE PEN 3ML. The contract has a firm fixed price, with a ceiling value of $42,294.38, and a period of performance through November 21, 2024. This contract is a child under a larger Indefinite Delivery Contract (IDC) between AmerisourceBergen and the DLA Troop Support Medical, valued at $999,999,999 and...
  • SPE2DB20D3505
    Indefinite Delivery Contract
  • SPE2DB20D3505-SPE2DB25FT7T7
    Delivery Order

This is a delivery order contract awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor, for the supply of OZEMPIC 0.25-0.5 MG/DOSE PEN 3ML. The contract has a firm fixed price of $25,403.91 and a completion date of January 13, 2025. It is not designated as a set-aside contract. AmerisourceBergen holds a larger Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued at $999,999,999 and running through November 2026, which serves as a primary vehicle for providing a comprehensive range of pharmaceutical products and medical supplies to support military healthcare programs globally.

Generated 4/11/25, 11:33 AM